Korean J Urol.  2015 Feb;56(2):99-108. 10.4111/kju.2015.56.2.99.

Current status of penile rehabilitation after radical prostatectomy

• Kim JH
• Lee SW

• KMID: 2133273
• DOI: http://doi.org/10.4111/kju.2015.56.2.99

Abstract

Although disease-free survival remains the primary goal of prostate cancer treatment, erectile dysfunction (ED) remains a common complication that affects the quality of life. Even though several preventive and therapeutic strategies are available for ED after radical prostatectomy (RP), no specific recommendations have been made on the optimal rehabilitation or treatment strategy. Several treatment options are available, including phosphodiesterase-5 inhibitors, vacuum erection devices, intracavernosal or intraurethral prostaglandin injections, and penile prostheses. Urologists must consider more effective ways to establish optimal treatments for ED after RP. ED is an important issue among patients with prostate cancer, and many patients hope for early ED recovery after surgery. This review highlights the currently available treatment options for ED after RP and discusses the limitations of each.

Keyword

Erectile dysfunction; Penis erection; Prostatectomy

MeSH Terms

Alprostadil/therapeutic use
Erectile Dysfunction/etiology/*rehabilitation
Humans
Male
Penile Implantation
Phosphodiesterase 5 Inhibitors/therapeutic use
Prostatectomy/*adverse effects/rehabilitation
Prostatic Neoplasms/*surgery
Risk Factors
Vacuum
Vasodilator Agents/therapeutic use
Alprostadil
Phosphodiesterase 5 Inhibitors
Vasodilator Agents

Reference

1. Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med. 2009; 6:2538–2546. PMID: 19515209.

2. Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med. 2013; 10(Suppl 1):102–111. PMID: 23387915.

3. Fode M, Ohl DA, Ralph D, Sonksen J. Penile rehabilitation after radical prostatectomy: what the evidence really says. BJU Int. 2013; 112:998–1008. PMID: 23826962.

4. Chen RC, Clark JA, Manola J, Talcott JA. Treatment 'mismatch' in early prostate cancer: do treatment choices take patient quality of life into account? Cancer. 2008; 112:61–68. PMID: 18040996.

5. Chung E, Gillman M. Prostate cancer survivorship: a review of erectile dysfunction and penile rehabilitation after prostate cancer therapy. Med J Aust. 2014; 200:582–585. PMID: 24882489.

6. Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012; 62:418–430. PMID: 22749850.

7. Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol. 2012; 62:273–286. PMID: 22575910.

8. Salonia A, Gallina A, Zanni G, Briganti A, Deho F, Sacca A, et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008; 53:564–570. PMID: 17761385.

9. Mulhall JP, Morgentaler A. Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med. 2007; 4:538–543. PMID: 17498093.

10. Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. Eur Urol. 2012; 62:261–272. PMID: 22575909.

11. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011; 306:1205–1214. PMID: 21934053.

12. Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005; 293:2648–2653. PMID: 15928287.

13. Rabbani F, Schiff J, Piecuch M, Yunis LH, Eastham JA, Scardino PT, et al. Time course of recovery of erectile function after radical retropubic prostatectomy: does anyone recover after 2 years? J Sex Med. 2010; 7:3984–3990. PMID: 20722784.

14. Bivalacqua TJ, Usta MF, Champion HC, Leungwattanakij S, Dabisch PA, McNamara DB, et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res. 2004; 16:21–29. PMID: 14963467.

15. Hu WL, Hu LQ, Song J, Li SW, Zheng XM, Cheng B, et al. Fibrosis of corpus cavernosum in animals following cavernous nerve ablation. Asian J Androl. 2004; 6:111–116. PMID: 15154084.

16. User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003; 169:1175–1179. PMID: 12576876.

17. Kaiho Y, Yamashita S, Arai Y. Optimization of sexual function outcome after radical prostatectomy using phosphodiesterase type 5 inhibitors. Int J Urol. 2013; 20:285–289. PMID: 23311962.

18. Mulhall JP, Bella AJ, Briganti A, McCullough A, Brock G. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med. 2010; 7(4 Pt 2):1687–1698. PMID: 20388165.

19. Nossaman BD, Gur S, Kadowitz PJ. Gene and stem cell therapy in the treatment of erectile dysfunction and pulmonary hypertension; potential treatments for the common problem of endothelial dysfunction. Curr Gene Ther. 2007; 7:131–153. PMID: 17430132.

20. Gratzke C, Strong TD, Gebska MA, Champion HC, Stief CG, Burnett AL, et al. Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J Urol. 2010; 184:2197–2204. PMID: 20851436.

21. Leungwattanakij S, Bivalacqua TJ, Usta MF, Yang DY, Hyun JS, Champion HC, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl. 2003; 24:239–245. PMID: 12634311.

22. Lysiak JJ, Yang SK, Klausner AP, Son H, Tuttle JB, Steers WD. Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation. J Urol. 2008; 179:779–785. PMID: 18082193.

23. Mullerad M, Donohue JF, Li PS, Scardino PT, Mulhall JP. Functional sequelae of cavernous nerve injury in the rat: is there model dependency. J Sex Med. 2006; 3:77–83. PMID: 16409220.

24. Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998; 10:113–120. PMID: 9647948.

25. Vignozzi L, Morelli A, Filippi S, Vannelli GB, Mungai S, Marini M, et al. Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Int J Impot Res. 2008; 20:60–67. PMID: 17703219.

26. Kovanecz I, Rambhatla A, Ferrini M, Vernet D, Sanchez S, Rajfer J, et al. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res. 2008; 20:202–212. PMID: 17882231.

27. Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J, et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int. 2008; 101:203–210. PMID: 17888043.

28. Mulhall JP, Muller A, Donohue JF, Mullerad M, Kobylarz K, Paduch DA, et al. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med. 2008; 5:1126–1136. PMID: 18331274.

29. Ozden E, Ozturk B, Kosan M, Tezel GG, Aki FT, Gur S, et al. Effect of sildenafil citrate on penile weight and physiology of cavernous smooth muscle in a post-radical prostatectomy model of erectile dysfunction in rats. Urology. 2011; 77:761.e1–761.e7. PMID: 21256544.

30. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology. 2006; 68:429–435. PMID: 16904479.

31. Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med. 2007; 4(4 Pt 1):908–916. PMID: 17627738.

32. Vignozzi L, Filippi S, Morelli A, Ambrosini S, Luconi M, Vannelli GB, et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med. 2006; 3:419–431. PMID: 16681467.

33. Sirad F, Hlaing S, Kovanecz I, Artaza JN, Garcia LA, Rajfer J, et al. Sildenafil promotes smooth muscle preservation and ameliorates fibrosis through modulation of extracellular matrix and tissue growth factor gene expression after bilateral cavernosal nerve resection in the rat. J Sex Med. 2011; 8:1048–1060. PMID: 21269401.

34. Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol. 2008; 18:613–620. PMID: 18832948.

35. Mulhall JP, Bivalacqua TJ, Becher EF. Standard operating procedure for the preservation of erectile function outcomes after radical prostatectomy. J Sex Med. 2013; 10:195–203. PMID: 22970890.

36. Chung E, Brock GB. Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction. Curr Urol Rep. 2011; 12:432–443. PMID: 21922167.

37. Briganti A, Di Trapani E, Abdollah F, Gallina A, Suardi N, Capitanio U, et al. Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy. J Sex Med. 2012; 9:608–617. PMID: 22189164.

38. Gallina A, Ferrari M, Suardi N, Capitanio U, Abdollah F, Tutolo M, et al. Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated? J Sex Med. 2012; 9:903–908. PMID: 22240189.

39. Gacci M, Bartoletti R, Figlioli S, Sarti E, Eisner B, Boddi V, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int. 2003; 91:196–200. PMID: 12581003.

40. Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med. 2009; 6:2032–2038. PMID: 19453918.

41. Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009; 55:334–347. PMID: 18986755.

42. Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med. 2009; 6(Suppl 3):353–362. PMID: 19267860.

43. Garcia-Cardoso J, Vela R, Mahillo E, Mateos-Caceres PJ, Modrego J, Macaya C, et al. Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. Int J Impot Res. 2010; 22:68–76. PMID: 19907424.

44. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008; 20:479–486. PMID: 18650827.

45. Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008; 54:924–931. PMID: 18640769.

46. Ayyathurai R, Manoharan M, Nieder AM, Kava B, Soloway MS. Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int. 2008; 101:833–836. PMID: 18190627.

47. Briganti A, Capitanio U, Chun FK, Karakiewicz PI, Salonia A, Bianchi M, et al. Prediction of sexual function after radical prostatectomy. Cancer. 2009; 115(13 Suppl):3150–3159. PMID: 19544544.

48. Descazeaud A, Debre B, Flam TA. Age difference between patient and partner is a predictive factor of potency rate following radical prostatectomy. J Urol. 2006; 176(6 Pt 1):2594–2598. PMID: 17085166.

49. Eastham JA, Scardino PT, Kattan MW. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol. 2008; 179:2207–2210. PMID: 18423693.

50. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004; 172(6 Pt 1):2227–2231. PMID: 15538237.

51. Michl UH, Friedrich MG, Graefen M, Haese A, Heinzer H, Huland H. Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. J Urol. 2006; 176:227–231. PMID: 16753406.

52. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000; 164:1929–1934. PMID: 11061884.

53. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int. 2008; 101:1279–1283. PMID: 18284406.

54. Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, Patel HR, et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol. 2014; 65:587–596. PMID: 24169081.

55. Raina R, Agarwal A, Ausmundson S, Lakin M, Nandipati KC, Montague DK, et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res. 2006; 18:77–81. PMID: 16107868.

56. Kohler TS, Pedro R, Hendlin K, Utz W, Ugarte R, Reddy P, et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int. 2007; 100:858–862. PMID: 17822466.

57. Bosshardt RJ, Farwerk R, Sikora R, Sohn M, Jakse G. Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. Br J Urol. 1995; 75:786–791. PMID: 7613837.

58. Broderick GA, McGahan JP, Stone AR, White RD. The hemodynamics of vacuum constriction erections: assessment by color Doppler ultrasound. J Urol. 1992; 147:57–61. PMID: 1729552.

59. Raina R, Lakin MM, Thukral M, Agarwal A, Ausmundson S, Montague DK, et al. Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res. 2003; 15:318–322. PMID: 14562131.

60. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997; 158:1408–1410. PMID: 9302132.

61. Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med. 2005; 2:532–540. PMID: 16422848.

62. Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int. 2010; 105:37–41. PMID: 19659465.

63. Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, Gilliland FD, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol. 2005; 174:646–650. PMID: 16006930.

64. Ramsawh HJ, Morgentaler A, Covino N, Barlow DH, DeWolf WC. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol. 2005; 174(4 Pt 1):1395–1398. PMID: 16145445.

65. Tal R, Jacks LM, Elkin E, Mulhall JP. Penile implant utilization following treatment for prostate cancer: analysis of the SEER-Medicare database. J Sex Med. 2011; 8:1797–1804. PMID: 21426495.

66. Nelson CJ, Choi JM, Mulhall JP, Roth AJ. Determinants of sexual satisfaction in men with prostate cancer. J Sex Med. 2007; 4:1422–1427. PMID: 17634054.

67. Son H, Park K, Kim SW, Paick JS. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl. 2004; 6:117–120. PMID: 15154085.

68. Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, et al. Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer. 2002; 95:1773–1785. PMID: 12365027.

69. Shindel A, Quayle S, Yan Y, Husain A, Naughton C. Sexual dysfunction in female partners of men who have undergone radical prostatectomy correlates with sexual dysfunction of the male partner. J Sex Med. 2005; 2:833–841. PMID: 16422807.

70. Canada AL, Neese LE, Sui D, Schover LR. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer. 2005; 104:2689–2700. PMID: 16294343.

71. Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006; 3:382–404. PMID: 16681465.

72. Kim SC, Song C, Kim W, Kang T, Park J, Jeong IG, et al. Factors determining functional outcomes after radical prostatectomy: robot-assisted versus retropubic. Eur Urol. 2011; 60:413–419. PMID: 21612859.

73. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2008; 179(5 Suppl):S97–S102. PMID: 18405769.

74. McCullough A. Penile change following radical prostatectomy: size, smooth muscle atrophy, and curve. Curr Urol Rep. 2008; 9:492–499. PMID: 18947515.

75. Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP. Peyronie's disease following radical prostatectomy: incidence and predictors. J Sex Med. 2010; 7:1254–1261. PMID: 20500447.